{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:43:46Z","timestamp":1775069026795,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T00:00:00Z","timestamp":1047427200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:p><jats:bold>BACKGROUND<\/jats:bold>: Most patients undergoing allogeneic marrow transplantation (alloBMT) require transfusions of RBCs. A retrospective analysis was performed to evaluate the utilization and risk factors for RBC transfusions including age and sex of recipient, HLA matching between donor and recipient, disease status at time of BMT, the occurrence of GVHD, ABO blood group compatibility, the source of progenitor cells and the Hb level before BMT (PT\u2010Hb).<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS<\/jats:bold>: Data from 519 consecutive patients receiving transplants between January 1995 and March 2000 were reviewed. The number of RBC transfusions was determined for the following periods: 0 to 60, 61 to 120, and 121 to 180 days after BMT.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>: The transfusion requirements were greatest during the first 60 days after BMT and decreased with time. The total number of units transfused to this cohort of patients was 5398, of which 3505 units were utilized within the first 2 months. The mean number \u00b1 SD of units transfused per patient from 0 to 60 days was 6.8 \u00b1 6.4; 61 to 120 days, 3.2 \u00b1 5.5; and 121 to 180 days, 2.0 \u00b1 4.6. An increased transfusion requirement was associated with lower PT\u2010Hb, major ABO mismatch between donor and recipient, BMT in patients with more advanced disease, use of unrelated donors, older age, and female sex by Spearman's correlation analysis. The source of progenitor cells and the development of GVHD did not influence transfusion requirements. Increased mortality during the 6\u2010month period after transplant was associated with lower PT\u2010Hb, use of unrelated donors, advanced disease status at BMT, and sex by Cox regression analysis. In a multivariate model, PT\u2010Hb remained significant when controlling for the other risk factors.<\/jats:p><jats:p><jats:bold>CONCLUSION<\/jats:bold>: The PT\u2010Hb was identified as an independent risk factor for RBC transfusions during alloBMT. As well, a lower PT\u2010Hb was found to be an independent risk factor for increased mortality during the 6\u2010month study period.<\/jats:p>","DOI":"10.1046\/j.1537-2995.2003.00339.x","type":"journal-article","created":{"date-parts":[[2004,12,29]],"date-time":"2004-12-29T20:57:42Z","timestamp":1104353862000},"page":"373-382","source":"Crossref","is-referenced-by-count":38,"title":["RBC transfusion requirements after allogeneic marrow transplantation: impact of the before\u2010transplant Hb level on transfusion and early survival"],"prefix":"10.1111","volume":"43","author":[{"given":"Anargyros","family":"Xenocostas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.C.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans A.","family":"Messner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,3,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(83)80028-8"},{"key":"e_1_2_6_3_2","first-page":"44","article-title":"Hematological support in patients undergoing allogeneic bone marrow transplantation.","volume":"108","author":"Osterwalder B","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01698131"},{"key":"e_1_2_6_5_2","first-page":"409","article-title":"Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non\u2010lymphocytic leukemia in first complete remission.","volume":"4","author":"Bensinger W","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.V84.10.3327.3327","article-title":"A controlled trial of recombinant human erythropoietin after bone marrow transplantation.","volume":"84","author":"Link H","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_7_2","first-page":"397","article-title":"Reduced blood transfusion requirements after allogeneic bone marrow transplantation: results of a randomized, double\u2010blind study with high dose erythropoietin.","volume":"13","author":"Klaesson S","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_8_2","first-page":"541","article-title":"Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial.","volume":"10","author":"Steegman JL","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_9_2","first-page":"129","article-title":"Prospective randomized double\u2010blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA\u2010identical sibling donors.","volume":"15","author":"Biggs JC","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_10_2","first-page":"649","article-title":"Bone marrow transplantation for leukemia and aplastic anemia: management of ABO incompatibility.","volume":"126","author":"Curtis JE","year":"1982","journal-title":"Can Med Assoc J"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0048"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701504"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603203141201"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables.","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_16_2","first-page":"163","article-title":"Transfusion problems associated with transplantation.","volume":"18","author":"Strorb R","year":"1981","journal-title":"Semin Hematol"},{"key":"e_1_2_6_17_2","unstructured":"Slichter SL. Principles of transfusion support before and after bone marrow transplantation. In: Forman SJ Blume KG Thomas ED editors. Bone marrow transplantation. Boston: Blackwell Scientific; 1994:273\u201098."},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V60.2.420.420","article-title":"Bone marrow transplantation with major ABO blood group incompatibility using erythrocyte depletion of marrow prior to infusion.","volume":"60","author":"Braine HG","year":"1982","journal-title":"Blood"},{"key":"e_1_2_6_19_2","first-page":"4609","article-title":"Immunohematologic problems arising from ABO incompatible bone marrow transplantation.","volume":"19","author":"Sniecinski IJ","year":"1987","journal-title":"Transplant Proc"},{"key":"e_1_2_6_20_2","first-page":"93","article-title":"Preparation of red\u2010blood\u2010cell depleted marrow for ABO\u2010incompatible marrow transplantation by density\u2010gradient separation using the IBM 2991 blood cell processor.","volume":"15","author":"Jin NR","year":"1987","journal-title":"Exp Hematol"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101183440303"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.537"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701510"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V83.7.1952.1952","article-title":"Use of recombinant erythropoietin in allogeneic bone marrow transplant donor\/recipient pairs.","volume":"83","author":"Mitus AJ","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/annonc\/8.suppl_3.S7","article-title":"Haematological toxicities associated with dose\u2010intensive chemotherapy, the role for and use of recombinant growth factors.","volume":"8","author":"Henry D","year":"1997","journal-title":"Ann Oncol"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2865"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1537-2995.2003.00339.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1537-2995.2003.00339.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1537-2995.2003.00339.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T22:45:17Z","timestamp":1734821117000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1537-2995.2003.00339.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1046\/j.1537-2995.2003.00339.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1537-2995.2003.00339.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}